April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Dose, Effects and Characteristics of Pilocarpine
Author Affiliations & Notes
  • G. L. Spaeth
    Glaucoma Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • G. M. Donaire
    Glaucoma Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • S. G. Li
    Glaucoma Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  G.L. Spaeth, None; G.M. Donaire, None; S.G. Li, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2482. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. L. Spaeth, G. M. Donaire, S. G. Li; Dose, Effects and Characteristics of Pilocarpine. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2482.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Results: : I- Treatment with pilocarpine in all concentrations greater than 0.5% had a highly significant lowering effect on IOP when compared with no treatment. Two groups were identified, those with and those without a significant IOP decrease. Pilocarpine concentration up to 8% did not lower IOP in the unresponsive group.II- Four times daily administration resulted in significantly lower IOP than daily or twice daily. Twice daily treatment was slightly more effective than daily treatment. A single daily dose caused a lowering of IOP of about 4 mmHg that lasted over 24 hours. Fifty nine hours after the last dose there was no evident effect.

Clinical Trial: : www.clinicaltrials.gov NTC00798700

Keywords: intraocular pressure • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×